Arch Venture Fund VII LP 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-02 5:02 pm Sale |
2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Arch Venture Fund VII LP | 0 0.000% |
-334,177 (Position Closed) |
Filing |